Serum levels of IFN-γ and IL-4 in hospitalised COVID-19 patients – evidence of reduced cytokine storm in discharged patients
DOI:
https://doi.org/10.15584/ejcem.2023.4.14Keywords:
cytokine storm, re-purposed treatment, SARS-CoV-2Abstract
Introduction and aim. Coronavirus disease 2019 is characterised by cytokine storm and it was managed with repurposed drugs, however the effect of this treatment on cytokine storm is unknown. The aim of the study was to investigate the effect of repurposed management on serum Th1 pro-inflammation cytokine (IFN-γ) and Th2 anti-inflammation cytokine (IL-4) in COVID-19 patients.
Material and methods. The levels of IFN-γ and IL-4 were determined in sera from 45 COVID-19 patients at admission followed-up till discharge after repurposed treatment using ELISA. The mean levels and proportions above normal reference ranges of IFN-γ and IL-4 were compared in COVID-19 at admission and discharge.
Results. The mean values of IFN-γ and IL-4 were significantly higher in COVID-19 patients at admission compared with discharged COVID-19 patients whereas IFN-γ:IL-4 ratio was significantly higher in discharged COVID-19 patients compared with admitted COVID-19 patients. Significantly higher proportion of COVID-19 patients at discharge had IFN-γ within the normal reference ranges compared with COVID-19 patients at admission whereas the proportions of COVID-19 patients at discharge and COVID-19 patients at admission having IL-4 within the normal reference ranges were the same.
Conclusion. Cytokine storm was evidenced in COVID-19 patients at admission and repurposed treatment suppressed pro-inflammation cytokine (IFN-γ) in most discharged COVID-19 patients.
Downloads
References
Arinola OG, Fashina OA, Ishola OC, et al. Demographic attributes of COVID-19 patients in an infectious disease center of Nigeria. African Journal of Clinical and Experimental Microbiology. 2021;22(1):21-27. doi: 10.4314/ajcem.v22i1.4
Worldometers. https://www.worldometers.info/coronavirus/country/nigeria/. Accessed March 23, 2023.
Arinola GO, Edem FV, Fashina OA, Olaniyan OA, Alonge TO. Cellular and Humoral Factors of Oxidative Burst in COVID-19 Patients with Malaria Parasiteamia. Annals of Epidemiology & Public Health. 2021;4(1):1060-1065.
Arinola OG, Onifade AA, Edem VF and Yaqub SA. Detection of anti SARS-COV 2 specific -IgG and -IgM antibodies in COVID-19 patients using rapid screening immunochromatographic cassettes. Annals of Epidemiology and Public Health. 2021;4(1): 1059-1062.
Arinola OG, Edem VF, Rahamon SK, Yaqub SA, Fashina AO, Alonge TO. SARS-CoV-2 Infection Screening Using Two Serological Testing Methods. Nigerian J Physiol Sci. 2020;35:117-121.
Arinola GO, Edem VF, Alonge TO. Respiratory Burst Functions in COVID-19 Nigerian Patients. J Basic Appl Res Biomed. 2021;7(1):24-28. doi: 10.51152/jbarbiomed
Arinola OG. Immune Responses During Human Coronavirus Infection:Suggestions For Future Studies: Nigerian J Physiol Sci. 2020;35:20-25.
Arinola OG. Serum Levels of Anti-Corona Virus Specific-IgG and -IgM Antibodies in COVID-19 Patients At Admission and At Discharge. Eur J Clin Exp Med. 2021;19(1):5-9. doi: 10.15584/ejcem.2021.1.1
Akinwumi JA, Fabian VF, Arinola OG. Cellular inflammatory indices in hospitalised Nigerian COVID-19 patients. Journal Health Science Research. 2021;6(2):19-26. doi: 10.7324/jhsr.2021.623
Arinola OG, Rahamon SK, Edem VF, Yaqub SA, Fashina OA, Alonge TO. Elevated plasma level of circulating immune complexes in Nigerian adults infected with Severe Acute Respiratory Syndrome Corona Virus-2. Arch Bas App Med. 2021;9:69-72.
Arinola OG, Edem FV, Alonge TO. Levels of Plasma C-reactive protein, Albumin and Pre-Albumin in Nigerian COVID-19 Patients. Ann Med Res. 2022;29(1):46-51. doi: 10.5455/annalsmedres.2020.08.839
Arinola OG, Onifade AA, Edem VF, Rahamon SK, Alonge OT. Immunometabolic Profile of Nigerian COVID-19 Patients. J Health Sci Med Res. 2023;41(5):e2023945. doi: 10.31584/jhsmr.2023945
Alonge O, Fowotade A, Bamidele F, et al. Clinical Outcome Of Corona Virus Disease-19 Patients In An Infectious Disease Center, Olodo, Ibadan, Oyo State, Nigeria. Clinical Medicine Insights. 2022;32;287-296. doi: 10.52845/CMI/2022-3-2-2
Olagunju A, Fowotade A, Olagunoye A, et al. Efficacy and safety of nitazoxanide plus atazanavir/ritonavir for the treatment of moderate to severe COVID-19 (NACOVID): A structured summary of a study protocol for a randomised controlled trial. Trials. 2021;4;22(1):3. doi: 10.1186/s13063-020-04987-8
Fowotade A, Bamidele F, Egbetola B, et al. A randomized, open-label trial of combined nitazoxanide and atazanavir/ritonavir for mild to moderate COVID-19. Front Med.2022;9:956123. doi: 10.3389/fmed.2022.956123
Onifade AA, Arinola OG. Albendazole reduces serum levels of inflammatory cytokines: Potential strategy for the management of cytokine storm. Saudi Journal of Biomedical Research. 2020;5(11):320-324. doi: 10.36348/sjbr.2020.v05i11.006
Islam MM, Islam S, Ahmed R, Majumder M, et al. Reduced IFN-γ levels along with changes in hematologic and immunologic parameters are key to COVID-19 severity in Bangladeshi patients. Exp Hematol. 2023;118:53-64.e1.doi: 10.1016/j.exphem.2022.11.006
Yang L, Liu S, Liu J, et al. COVID-19: immunopathogenesis and Immunotherapeutics. Sig Transduct Target Ther. 2020;5:128. doi: 10.1038/s41392-020-00243-2
Chang Y, Bai M, You Q. Associations between Serum Interleukins (IL-1β, IL-2, IL-4, IL-6, IL-8, and IL-10) and Disease Severity of COVID-19: A Systematic Review and Meta-Analysis. Biomed Res Int. 2022;2022:2755246. doi: 10.1155/2022/2755246
Luo W, Zhang JW, Zhang W, Lin YL, Wang Q. Circulating levels of IL-2, IL-4, TNF-α, IFN-γ, and C-reactive protein are not associated with severity of COVID-19 symptoms. J Med Virol. 2021;93(1):89-91. doi: 10.1002/jmv.26156
Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-1062. doi:10.1016/S0140-6736(20)30566-3
Kak G, Raza M, Tiwari BK. Interferon-gamma (IFN-γ): exploring its implications in infectious diseases. Biomol Concepts. 2018;9:64-79. doi: 10.1515/bmc-2018-0007
Costela-Ruiz VJ, R Illescas-Montes, JM Puerta-Puerta, C Ruiz, L. Melguizo-Rodriguez. SARS-CoV-2 infection: the role of cytokines in COVID-19 disease. Cytokine Growth Factor Rev. 2020;54:62-75. doi: 10.1016/j.cytogfr.2020.06.001
Karki R, Sharma BR, Tuladhar S, et al. Synergism of TNF-α and IFN-γ triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 infection and cytokine shock syndromes. Cell. 2021;184:149-168. doi: 10.1016/j.cell.2020.11.025
Fu L, Wang B, Yuan T, et al. Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: A systematic review and meta-analysis. J Infect. 2020;80(6):656-665. doi: 10.1016/j.jinf.2020.03.041
Tang Y, Liu J, Zhang D, Z Xu, Ji J, Wen C. Cytokine storm in COVID-19: the current evidence and treatment strategies. Front Immunol. 2020;11:1708. doi: 10.3389/fimmu.2020.01708
Romagnani S. The Th1/Th2 paradigm. Immunol Today. 1997;18:263-266.
Alfadda AA, Siddiqui K, Rafiullah M, et al. Early Cytokine Signatures of Hospitalized Mild and Severe COVID-19 Patients: A Prospective Observational Study. J Inflamm Res. 2023;16:2631-2643. doi: 10.2147/JIR.S408663
Pisoschi AM, Pop A, Iordache F, Stanca L, Geicu OI, Bilteanu L, Serban AI. Antioxidant, anti-inflammatory and immunomodulatory roles of vitamins in COVID-19 therapy. Eur J Med Chem. 2022;232:114175. doi: 10.1016/j.ejmech.2022.114175
Gęgotek A, Skrzydlewska E. Antioxidative and Anti-Inflammatory Activity of Ascorbic Acid. Antioxidants (Basel). 2022;11(10):1993. doi: 10.3390/antiox11101993
Rahamon SK, Arinola OG, Charles-Davies MA, et al. Serum levels of vitamin D and tumour necrosis factor-alpha in adults with metabolic syndrome. Eur J Clin Exp Med. 2021;19(4):306-312. doi: 10.15584/ejcem.2021.4.3
Arinola OG, Edem VF. Levels of interleukin (IL)-8 and catalase have correlations with zinc in healthy adults: implications for inflammatory conditions. Ann Medl Res. 2021;28(11):1957-1960. doi: 10.5455/annalsmedres.2020.08.806
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
